Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging

Fig. 6

Immunohistochemical analysis (IHC) on excised BT-474 and JIMT-1 tumors show human epidermal growth factor receptor 2 (HER2) and pSrc (Y416) changes. IHC (× 40 magnification) was performed on excised BT-474 (a) and JIMT-1 (b) tumors showing HER2 (top) and phosphorylated Src (pSrc) (Y416, bottom) expression with (right) and without (left) dasatinib treatment (a)

Back to article page
\